Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
We haven't written up this one. CBC News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Moderna, Merck mRNA cancer vaccine prevents melanoma from returning thehill.com
- Merck, Moderna Melanoma Vaccine Study Succeeds bloomberg.com
- Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine endpoints.news
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial qz.com
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com
- Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning nytimes.com
- Moderna share price doubles on melanoma vaccine trial success ft.com
